



J. Am. Chem. Soc., 1996, 118(22), 5322-5323, DOI:[10.1021/ja9607906](https://doi.org/10.1021/ja9607906)

Terms & Conditions

Electronic Supporting Information files are available without a subscription to ACS Web Editions. The American Chemical Society holds a copyright ownership interest in any copyrightable Supporting Information. Files available from the ACS website may be downloaded for personal use only. Users are not otherwise permitted to reproduce, republish, redistribute, or sell any Supporting Information from the ACS website, either in whole or in part, in either machine-readable form or any other form without permission from the American Chemical Society. For permission to reproduce, republish and redistribute this material, requesters must process their own requests via the RightsLink permission system. Information about how to use the RightsLink permission system can be found at <http://pubs.acs.org/page/copyright/permissions.html>



ACS Publications

MOST TRUSTED. MOST CITED. MOST READ.

Copyright © 1996 American Chemical Society

Supporting Information for :

**Anionic Cyclizations of α -Aminoorganolithiums.
Determination of the Stereoselectivity at the Carbanion Center
and the Synthesis of (+)-Pseudoheliotridane.**

Iain Coldham,* Richard Hufton and David J. Snowden


Department of Chemistry, University of Exeter, Stocker Road, Exeter, EX4 4QD, U.K.

A procedure for the anionic cyclization, electrophilic quench of aminomethylstannane **1** and spectroscopic data for compounds **3a-i**, **5-7** and **8a-d** (8 pages):

Anionic cyclization-electrophilic quench of aminomethylstannane **1:**

n-Butyllithium (0.44 cm³, 0.64 mmol, 1.48 mol dm⁻³ in hexanes) was added to aminomethylstannane **1** (160 mg, 0.34 mmol) in dry hexane-diethylether (2 cm³, 10:1) at -78 °C under argon. After 10 min. the mixture was warmed to room temperature over 30 min. and allowed to stand for 3 h. The mixture was cooled to -78 °C and quenched with the electrophile (3.20 mmol). The solvents were removed under reduced pressure and the residue was purified by column chromatography on silica gel, eluting with CH₂Cl₂-EtOH-NH₃ (200:3:2) or EtOAc-light petroleum (b.p. 40-60°C) (1:10) to give the pyrrolidine **3**.

Pyrrolidine **3a** (quench with methanol, 74%):



*R*_F [hexane-ethyl acetate (7:1)] 0.09.

IR (neat) 1605 and 1495 cm⁻¹ (Ph).


¹H NMR (300 MHz, CDCl₃) δ 7.43-7.18 (5H, m, C₆H₅), 3.62 (2H, ABq, *J* 12.8 Hz, CH₂Ph), 2.83 [1H, dd, *J* 9.0 and 7.5 Hz, NCH_AH_BCH(CH₃)], 2.71 (1H, ddd, *J* 9.0, 7.9 and 5.7 Hz, NCH_CH_DCH₂), 2.47 (1H td, *J* 9.0 and 6.4 Hz, NCH_CH_DCH₂), 2.26 [1H, ddqdd, *J* 12.0, 8.4, 7.5, 7.3 and 6.2 Hz, CH(CH₃)], 2.04 (1H, dtd, *J* 12.0, 9.0 and 6.2 Hz, NCH₂CH_EH_F), 2.01 [1H, dd, *J* 9.0 and 7.3 Hz, NCH_AH_BCH(CH₃)], 1.35 (1H, dtd, *J* 12.0, 9.0 and 6.2 Hz, NCH₂CH_EH_F) and 1.03 (3H, d, *J* 6.7 Hz, CHCH₃).

¹³C NMR (75 MHz, CDCl₃) δ 139.37, 128.55, 128.16, 126.81, 62.13, 60.80, 54.10, 32.65, 31.88 and 20.37.

HRMS (EI) (Found: M⁺, 175.1360. C₁₂H₁₇N requires M, 175.1361).

m/z 175 (38%, M⁺), 160 (2, M-CH₃), 91 (100, CH₂Ph) and 84 (21, M-CH₂Ph).

Pyrrolidine **3b** (quench with Me₄Sn, 68%)



*R*_F [hexane-ethyl acetate (7:3)] 0.27.

J-S323-2


IR (neat) 1605 and 1496 cm⁻¹ (Ph).

¹H NMR (300 MHz, CDCl₃) δ 7.36-7.21 (5H, m, C₆H₅), 3.59 (2H, ABq, *J* 13 Hz, CH₂Ph), 2.84 [1H, dd, *J* 8.5 and 7.0 Hz NCH_AH_BC(H)CH₂Sn], 2.73-2.64 (1H, m, NCH_ACH_DCH₂), 2.50-2.37 [2H, m, CH(CH₂Sn) and NCH_CH_DCH₂], 2.20-2.11 (1H, m, NCH₂CH_EH_F), 2.01 [1H, dd, *J* 8.5 and 7.5 Hz, NCH_AH_BC(H)CH₂Sn], 1.31 (1H, dtd, *J* 12.5, 9.0 and 6.0 Hz, NCH₂CH_EH_F), 0.97 (2H, d, *J* 7.5 Hz, CH₂Sn) and 0.06 [9H, s, Sn(CH₃)₃].

¹³C NMR (75 MHz, CDCl₃) δ 139.32, 128.87, 128.15, 126.80 64.15, 60.84, 54.06, 36.05, 34.47, 18.37 and -9.67.

HRMS (EI) (Found: M⁺ - CH₃, 324.0786. C₁₄H₂₂NSn requires M - CH₃, 324.0774). *m/z* 324 (75%, M⁺), 174 [97, M-(CH₃)₃Sn] and 91 (100, CH₂Ph).

Pyrrolidine 3c (quench with benzaldehyde, 90%)



Two diastereomers (1:1), R_F (CH₂Cl₂-EtOH-conc. NH₃, 100:8:1) 0.45.

IR (neat) 3360 (O-H), 1600 and 1495 cm⁻¹ (Ph).


¹H NMR (300 MHz, CDCl₃) δ 7.44-7.15 [10H, m, CH₂C₆H₅ and CH(OH)C₆H₅], 4.72 (0.5H, dd, *J* 9.1 and 4.4 Hz, CHOH), 4.66 (0.5H, dd, *J* 8.2 and 5.3 Hz, CH'OH'), 3.95 (1H, broad s, CHOH), 3.71 (1H, ABq, *J* 12.6 Hz, CH₂Ph), 3.68 (1H, ABq, *J* 12.6 Hz, CH₂Ph'), 2.88-2.68 (1H, m, NCH_AH_BCH(CH₂) and NCH_AH_BCH(CH₂')], 2.71-2.58 (2H, m, NCH₂CH₂ and NCH'₂CH'), 2.53-30 [2H, m, NH_ACH_BCH(CH₂), NCH_AH'_BCH(CH₂')', NCH₂CH(CH₂) and NCH₂CH(CH₂')], 2.12-1.93 (1H, m, NCH₂CH_CH_D and NCH₂CH'_CH_D'), 1.91-1.64 (2.5H, m, CH₂CHOH, CH'CHOH' and NCH₂CH_CH_D) and 1.59-1.44 (0.5H, m, NCH₂CH_CH_D).

¹³C NMR (75 MHz, CDCl₃) δ 145.29, 145.17, 138.89, 138.45, 128.94, 128.89, 128.38, 128.35, 128.29, 128.26, 128.19, 127.35, 127.14, 127.12, 126.97, 125.92, 125.86, 73.19, 71.77, 60.57, 60.45, 60.41, 60.03, 53.66, 53.43, 45.08, 34.61, 34.24, 30.94 and 28.64.

HRMS (EI) (Found: M⁺, 281.1786. C₁₉H₂₃NO requires M, 281.1780).

m/z 281 (12%, M⁺), 190 (5, M-CH₂Ph), 174 [4, M-CH(OH)C₆H₅], 159 (14, M-C₈H₈O), 120 (80, C₈H₈O), 91 (100, CH₂Ph) and 77 (8, C₆H₅).

Pyrrolidine 3d (quench with acrolein, 65%)



Two diastereomers (1:1), R_F (CH₂Cl₂-EtOH-conc. NH₃, 100:8:1) 0.32 and 0.23.

IR (neat) 3370 (O-H), 1640 (C=C), 1605 and 1495 cm⁻¹ (Ph).

¹H NMR (300 MHz, CDCl₃) δ 7.39-7.20 (5H, m, C₆H₅), 5.95-5.78 (1H, m, CH=CH₂ and CH'=CH₂'), 5.28-5.03 (2H, m, CH=CH₂ and CH=CH₂'), 4.23-4.04 (1H, m, CHOH and CH'OH'), 3.77-3.46 (2H, 2 x ABq, *J* 12.7 and 13 Hz, CH₂Ph and CH₂Ph'), 2.85-2.71 [1H, m, NCH_AH_BCH(CH₂) and NCH'_AH_BCH(CH₂')], 2.64-2.22


J-5323-3

[4H, m, $\text{NCH}_\text{A} \text{H}_\text{B} \text{CH}(\text{CH}_2)$, $\text{NCH}_\text{A} \text{H}'_\text{B} \text{CH}(\text{CH}_2)'$, $\text{NCH}_2 \text{CH}_2$ and $\text{NCH}'_2 \text{CH}'_2$], 2.15-1.93 (1.5H, m, $\text{NCH}_2 \text{CH}_\text{C} \text{H}_\text{D}$, $\text{NCH}_2 \text{CH}'_\text{C} \text{H}_\text{D}'$ and $\text{NCH}_2 \text{CH}_\text{C} \text{H}'_\text{D}'$) and 1.71-1.43 (2.5H, m, $\text{CH}_2 \text{CHOH}$, $\text{CH}'_2 \text{CHOH}'$ and $\text{NCH}_2 \text{CH}_\text{C} \text{H}_\text{D}$).

HRMS (EI) (Found: M^+ , 231.1628. $\text{C}_{15}\text{H}_{21}\text{NO}$ requires M , 231.1623).

m/z 231 (17%, M^+), 214 (2, M-OH), 174 [10, M- $\text{CH}(\text{OH})\text{CH}=\text{CH}_2$], 160 (10, M- $\text{CH}_2\text{CH}(\text{OH})\text{CH}=\text{CH}_2$] and 91 (100, CH_2Ph).

Pyrrolidine 3e (quench with pivalaldehyde, 52%)



Two diastereomers (1:1), R_F (hexane-ethyl acetate 1:1) 0.02.

IR (neat) 3410 (O-H), 1605 and 1495 cm^{-1} (Ph).


^1H NMR (300 MHz, CDCl_3) δ 7.40-7.18 (5H, m, C_6H_5), 3.74-3.57 (2H, m, CH_2Ph and $\text{CH}_2\text{Ph}'$), 3.21 (1H, dd, J 10.9 and 10.9 Hz, CHOH and $\text{CH}'\text{OH}'$), 2.91 (1H, broad s, CHOH), 2.90-2.28 (6H, m, 3 x CH_2 ring protons), 2.15-1.97 [1H, m, $\text{NCH}_2\text{CH}(\text{CH}_2)$ and $\text{NCH}_2\text{CH}'(\text{CH}_2)'$], 1.65-1.32 (2H, m, CH_2CHOH and $\text{CH}'_2\text{CHOH}'$) and 0.80 [9H, s, $\text{C}(\text{CH}_3)_3$].

^{13}C NMR (75 MHz, CDCl_3) δ 133.05, 132.81, 123.84, 123.76, 123.10, 122.00, 121.91, 73.16, 55.20, 55.14, 55.06, 54.82, 48.40, 48.35, 31.63, 31.59, 29.62, 29.60, 29.52, 29.52, 29.46, 25.65, 25.33, 24.50, 20.63 and 20.46.

HRMS (EI) (Found: M^+ , 261.2097. $\text{C}_{17}\text{H}_{27}\text{NO}$ requires M , 261.2093).

m/z 261 (26%, M^+), 204 (27, M- C_4H_9), 120 (100, $\text{CH}_2\text{NHCH}_2\text{Ph}$) and 57 (27, C_4H_9).

Pyrrolidine 3f (quench with acetaldehyde, 68%)



Two diastereomers (2:1), R_F (hexane-ethyl acetate, 1:1) 0.01.

IR (neat) 3370 (O-H), 1605 and 1495 cm^{-1} (Ph).


^1H NMR (300 MHz, CDCl_3) δ 7.41-7.13 (5H, m, C_6H_5), 3.70-3.62 (3H, m, CH_2Ph , $\text{CH}_2\text{Ph}'$, CHOH and $\text{CH}'\text{OH}'$), 3.20 (1H, broad s, CHOH), 2.87-1.88 [7H, m, 3 x CH_2 ring protons, $\text{NCH}_2\text{CH}(\text{CH}_2)$ and $\text{NCH}_2\text{CH}'(\text{CH}_2)'$], 1.80-1.42 (2H, m, CH_2CHOH and $\text{CH}'_2\text{CHOH}'$) and 1.20-1.13 (3H, m, CH_3 and CH_3').

^{13}C NMR (75 MHz, CDCl_3) δ 138.43, 138.30, 128.97, 128.80, 128.40, 128.32, 128.30, 127.22, 127.14, 127.11, 67.17, 66.58, 60.46, 60.37, 60.15, 57.94, 53.67, 53.56, 44.75, 44.35, 38.87, 34.56, 34.20, 30.92, 26.96, 23.82 and 23.60.

HRMS (EI) (Found: M^+ , 219.1623. $\text{C}_{14}\text{H}_{21}\text{NO}$ requires M , 219.1623).

m/z 219 (4%, M^+), 204 (1, M- CH_3), 174 (2, M- CH_3CHOH), 91 (100, CH_2Ph), 128 (4, M- CH_2Ph) and 77 (5, C_6H_5).

J-5323-4


Pyrrolidine **3g** (quench with allyl bromide, 58%)*R*_F (hexane-ethyl acetate 1:1) 0.20.IR (neat) 1605 and 1495 cm⁻¹ (Ph).

¹H NMR (300 MHz, CDCl₃) δ 7.39-7.18 (5H, m, C₆H₅), 5.81 (1H, ddt, *J* 17.0, 10.5 and 6.5 Hz, CH₂=CH), 5.00 (1H, dq, *J* 18.0 and 2.0 Hz, CH_AH_B=CH), 4.94 (1H, d, *J* 10.0 Hz, CH_{CHD}=CH), 3.61 (2H, ABq, *J* 12.0 Hz, CH₂Ph), 2.83 [1H, dd, *J* 8.5 and 7.5 Hz, NCH_{CHD}CH(CH₂)], 2.71 (1H, ddd, *J* 9.0, 7.9 and 5.5 Hz, NCH_EH_FCH₂), 2.44 (1H td, *J* 8.9 and 6.5, NCH_EH_FCH₂), 2.26-2.10 [1H, m, CH(CH₂)], 2.10-1.94 [4H, m, NCH_AH_BCH(CH₂), NCH₂CH_GH_H and CH₂=CHCH₂], 1.47 (2H, ABq, *J* 7.5 Hz, CH₂=CHCH₂CH₂) and 1.50-1.35 (1H, m, NCH₂CH_GH_H).

¹³C NMR (75 MHz, CDCl₃) δ 139.37, 138.75, 128.81, 128.17, 126.81, 114.33, 60.82, 60.49, 53.92, 37.08, 34.95, 32.54 and 30.77.

HRMS (EI) (Found: *M*⁺, 215.1672. C₁₅H₂₁N requires *M*, 215.1674).

m/z 215 (19%, M⁺), 174 (13, M-C₃H₅), 138 (9, M-C₆H₅) and 91 (100, CH₂Ph).


Pyrrolidine **3h** (quench with CD₃OD, 73%)*R*_F (hexane-ethyl acetate 1:1) 0.09.IR (neat) 1605 and 1495 cm⁻¹ (Ph).

¹H NMR (300 MHz, CDCl₃) δ 7.39-7.20 (5H, m, C₆H₅), 3.62 (2H, ABq, *J* 12.0 Hz, CH₂Ph), 2.83 [1H, dd, *J* 8.7 and 7.5 Hz, NCH_AH_BCH(CH₂D)], 2.71 (1H, ddd, *J* 9.0, 8.0 and 5.5 Hz, NCH_{CHD}CH₂), 2.48 (1H ddd, *J* 9.0, 8.0 and 5.5 Hz NCH_{CHD}CH₂), 2.26 [1H, broad m, CH(CH₂D)], 2.12-1.96 [2H, m, NCH₂CH_EH_F and NCH_AH_BCH(CH₂D)] and 1.02 (2H, m, CHCH₂D).

¹³C NMR (75 MHz, CDCl₃) δ 139.57, 128.91, 128.25, 126.88, 62.22, 60.84, 54.14, 32.71, 31.87, 20.38, 20.08 and 19.77.

HRMS (EI) (Found: *M*⁺, 176.1424. C₁₂H₁₆DN requires *M*, 176.1425).

m/z 176 (17%, M⁺), 91 (64, CH₂Ph), 84 (18, M-CH₂Ph), 77 (12, C₆H₅) and 55 (100, C₄H₇).

Pyrrolidine **3i** (quench with benzophenone, 82%)*R*_F (CHCl₃-MeOH 20:1) 0.27.IR (neat) 3340 (O-H), 1600 and 1490 cm⁻¹ (Ph).

J-5323-5

¹H NMR (400 MHz, CDCl₃) δ 7.55-7.25 (15H, m, 3xPh) 3.61 (2H, ABq, *J* 15.0 Hz, CH₂Ph), 2.69 [1H, dd, *J* 8.0 and 6.0 Hz, NCH_AH_BCH(CH₂)], 2.60-2.50 (2H, m, NCH₂CH₂), 2.46 [2H, dd, *J* 5.5 and 1.5 Hz, CH₂C(OH)], 2.36-2.23 [2H, m, NCH_AH_BCH(CH₂) and NCH_AH_BCH(CH₂)], 1.92-1.81 (1H, m, NCH₂CH_CHD) and 1.52-1.41 (1H, m, NCH₂CH_CHD).

¹³C NMR (100 MHz, CDCl₃) δ 147.64, 147.37, 137.46, 129.24, 128.36, 128.11, 127.35, 126.79, 126.73, 126.06, 126.04, 78.01, 60.57, 60.21, 53.13, 46.87, 33.56 and 31.70.

HRMS (EI) (Found: M⁺, 357.2076. C₂₅H₂₇NO requires M, 357.2092).


m/z 357 (3%, M⁺), 174 [15, M-C(OH)Ph₂], 159 [79, M-CH₂C(OH)Ph₂], 91 (100, CH₂Ph) and 77 (22, C₆H₅).

Pyrrolidine (-)-4 and the corresponding Mosher amide were prepared according to the procedure described by Beak.^{1b}

Pyrrolidine (-)-4 (94% ee)

[α]_D²³ -136 (*c* 2.7 in CHCl₃).

Pyrrolidine (+)-5 (61%)



R_F [light petroleum (b.p. 40-60°C) : EtOAc (9:1)] 0.29.

[α]_D²³ +189 (*c* 2.8 in EtOH).

IR (neat) 1640 (C=C), 1605 cm⁻¹ (C=O).


¹H NMR (400 MHz, C₆D₆) δ 6.13 (1H, ddt, *J* 17, 10, 7 Hz, CH₂=CH), 5.10 (1H, ddd, *J* 9, 3.5, 1.5 Hz, CHH=CH), 5.05 (1H, dd, *J* 4 and 1.5 Hz, CHH=CH), 3.19 (1H, t, *J* 7 Hz, NCHSn), 3.01 (1H, t, *J* 10 Hz, CHHN), 2.93 (1H, t, *J* 8 Hz, CHHN), 2.87 (2H, d, *J* 7 Hz, O=CCH₂), 1.96-1.45 (4H, m, NCH₂CH₂CH₂), 1.73 [6H, m, (CH₂)₃Sn], 1.49 [6H, sextet, *J* 7.5 Hz, (CH₃CH₂CH₂CH₂)₃Sn], 1.09 [6H, m, (CH₃CH₂CH₂CH₂)₃Sn], and 1.04 {9H, t, *J* 7.5 Hz, [CH₃(CH₂)₃]₃Sn}].

¹³C NMR (100 MHz, C₆D₆) δ 166.95, 132.51, 116.62, 46.48, 39.71, 29.67, 29.46, 27.82, 27.61, 13.77 and 10.90.

HRMS (EI) (Found: M⁺, 429.2068. C₂₀H₃₉NOSn¹¹⁹ requires M, 429.2054).

m/z 429 (0.5%, M⁺), 372 (62, M-Bu), 70 (100, C₄H₆O).

Pyrrolidine (+)-6 (89%)



R_F [light petroleum (b.p. 40-60°C) : EtOAc (4:1)] 0.15.

[α]_D²³ +107 (*c* 2.6 in EtOAc).

IR (neat) 2870 (C-H), 1640 cm⁻¹ (C=C).

¹H NMR (400 MHz, C₆D₆) δ 6.00 (1H, ddt, *J* 17, 10, 6 Hz, CH₂=CH), 5.17 (1H, d, *J* 16 Hz, CHH=CH), 5.11 (1H, d, *J* 10 Hz, CHH=CH), 3.07-2.97 (2H, m, CH₂CH=CH₂), 2.51 (2H, dd, *J* 10 and 7 Hz, CH₂CH₂CH₂N), 2.45-2.23 (2H, m, NCH₂CH₂CH=CH₂), 2.10-1.92 (4H, m, NCH₂CH₂CH₂), 1.88 (1H, t, *J* 9 Hz,

J-5323-6


NCH₂Sn), 1.71 [6H, m, (CH₂)₃Sn], 1.47 [6H, sextet, *J* 8 Hz, (CH₃CH₂CH₂CH₂)₃Sn], 1.08 [6H, m, (CH₃CH₂CH₂CH₂)₃Sn] and 1.04 {9H, t, *J* 7 Hz, [CH₃(CH₂)₃]₃Sn}.

¹³C NMR (100 MHz, C₆D₆) δ 137.19, 115.00, 57.51, 56.46, 53.66, 33.86, 29.71, 29.54, 27.72, 24.97, 13.68 and 9.22.

HRMS (EI) (Found: M⁺, 415.2257. C₂₀H₄₁NSn¹¹⁹ requires M, 415.2261).

m/z 415 (0.1%, M⁺), 124 (100, M-SnBu₃), 55 (72, C₄H₇).

Pseudoheliotridane (+)-7 (87%), data corresponds with lit.¹⁰



M.p. 230-234 °C of picrate salt.

R_F [CH₂Cl₂-MeOH-NH₃ (9:1:0.1)] 0.10.

[α]_D²³ +6.8 (*c* 0.5 in EtOH, free base).

IR (KBr disk, picrate salt) 2990 (C-H), 1560 cm⁻¹ (NO₂).

¹H NMR (400 MHz, CDCl₃, picrate salt) δ 8.85 (2H, s, C₆H₂ of picrate), 4.04-4.00 (1H, m, NCHCHMe), 3.95-3.85 (1H, m, NCHHCH₂CHMe), 3.74-3.64 (1H, m, NCHHCH₂CHMe), 3.13-3.03 (1H, m, NCHHCH₂CH₂), 2.92-2.83 (1H, m, NCHHCH₂CH₂), 2.33-2.26 (1H, m, CHHCHMe), 2.27-2.17 (2H, m, NCH₂CHHCH₂ and CHHCHMe), 2.16-2.07 (1H, m, NCH₂CHHCH₂), 2.07-1.98 (1H, m, NCH₂CH₂CHH), 1.98-1.91 (1H, m, CHMe), 1.91-1.80 (1H, m, NCH₂CH₂CHH) and 1.21 (3H, d, *J* 6.5 Hz, CH₃).

¹³C NMR (100 MHz, CDCl₃, picrate salt) δ 162.08, 141.60, 128.55, 126.60, 74.07, 55.63, 55.45, 40.02, 33.89, 29.31, 24.78 and 16.69.

HRMS (EI, free base) (Found: M⁺, 125.1201. C₈H₁₅N requires M, 125.1204).


HRMS (EI, picrate salt) (Found: M⁺+H, 355.1243. C₁₄H₁₉N₄O₇ requires M, 355.1254).

m/z 355 (1.3%, M⁺), 229 (4, picric acid), 125 (51, C₈H₁₅N), 83 (100, C₅H₉N).

Found: C, 47.47; H, 5.04; N, 15.51. C₁₄H₁₈N₄O₇ requires C, 47.46; H, 5.12; N, 15.81.

The Pirkle solvating agent (0.03 mmol) splits and shifts the CH₃ group of the free base, pseudoheliotridane (5 mg, 0.04 mmol) in CDCl₃ (0.7 cm³) from δ 1.02 (3H, d, *J* 6.5 Hz) to δ 0.69 (3H, d, *J* 4 Hz) and δ 0.67 (3H, d, *J* 4 Hz).

Pyrrolizidine (±)-8a (quench with CD₃OD, 50%)



M.p. 235-236 °C of picrate salt.

R_F [CH₂Cl₂-MeOH (9:1)] 0.60.

IR (CDCl₃, picrate salt) 2960 (C-H), 1570 cm⁻¹ (NO₂).

¹H NMR (400 MHz, CDCl₃, picrate salt) δ 8.82 (2H, s, C₆H₂ of picrate), 4.05-3.99 (1H, m, NCHCHCH₂D), 3.95-3.85 (1H, m, NCHHCH₂CHCH₂D), 3.74-3.64 (1H, m, NCHHCH₂CHCH₂D), 3.13-3.03 (1H, m, NCHHCH₂CH₂), 2.93-2.83 (1H, m, NCHHCH₂CH₂), 2.33-2.26 (1H, m, CHHCHCH₂D), 2.27-2.17 (2H, m, NCH₂CHHCH₂ and CHHCHCH₂D), 2.16-2.07 (1H, m, NCH₂CHHCH₂), 2.07-1.98 (1H, m, CH CH₂D), 1.98-1.91 (1H, m, NCH₂CH₂CHH), 1.91-1.82 (1H, m, NCH₂CH₂CHH) and 1.25-1.15 (2H, dt, *J* 2 and 6.5 Hz, CH₂D).


J-5323-7

¹³C NMR (100 MHz, CDCl₃, picrate salt) δ 162.38, 141.71, 128.07, 126.58, 74.08, 55.62, 55.45, 39.91, 33.86, 29.30, 24.78, 16.60, 16.41 and 16.21.

HRMS (EI, picrate salt) (Found: M⁺, 355.1244. C₁₄H₁₇DN₄O₇ requires M, 355.1238).

m/z 355 (0.1%, M⁺), 229 (23, picric acid), 126 (25, C₈H₁₆N), 83 (100, C₅H₉N). Found: C, 47.80; H, 5.18; N, 15.62. C₁₄H₁₇DN₄O₇ requires C, 47.32; H, 4.82; N, 15.77.

Pyrrolizidine (+)-8b (quench with benzophenone, 62%)



M.p. 164-166 °C.

R_F [CH₂Cl₂-MeOH (9:1)] 0.11.

[α]_D²³ +19.6 (c 0.5 in EtOH).

IR (KBr disk) 3420 (O-H), 2960 cm⁻¹ (C-H).

¹H NMR (400 MHz, CD₃OD) δ 7.47-7.13 (10H, m, 2xPh), 3.08 (1H, dt, J 5 and 8 Hz, NCHHCH₂CHCH₂CO), 3.00-2.92 (1H, m, NCHHCH₂CO), 2.80 (1H, dt, J 11 and 6.5 Hz, NCHHCH₂CH₂), 2.55-2.45 (2H, m, NCH₂CH₂CHCH₂CO), 2.42-2.32 (1H, m, NCHHCH₂CH₂), 2.32-2.24 (1H, m, NCHHCH₂CHCH₂CO), 1.82-1.58 (5H, m, NCH₂CH₂CH₂ and CHCH₂CO) and 1.47-1.31 (2H, m, CH₂CO).

¹³C NMR (100 MHz, CD₃OD) δ 148.09, 148.03, 127.50, 127.47, 126.07, 126.05, 125.88, 77.09, 71.05, 54.54, 54.40, 45.29, 41.45, 34.88, 30.36 and 24.68.

HRMS (EI) (Found: M⁺, 307.1941. C₂₁H₂₅NO requires M, 307.1936).

m/z 307 (1%, M⁺), 183 (4.5, Ph₂COH), 124 (100, C₈H₁₄N).

Pyrrolizidine (\pm)-8c (quench with TMSCl, 63%)



M.p. 145-146 °C of picrate salt.

R_F [CH₂Cl₂-MeOH (9:1)] 0.64.

IR (CDCl₃, picrate salt) 2960 (C-H), 1565 cm⁻¹ (NO₂).


¹H NMR (400 MHz, CDCl₃, picrate salt) δ 8.87 (2H, s, C₆H₂ of picrate), 4.08-3.97 (1H, m, NCHHCH₂Si), 3.95-3.84 (1H, m, NCHHCH₂CHCH₂Si), 3.74-3.63 (1H, m, NCHHCH₂CHCH₂Si), 3.11-3.03 (1H, m, NCHHCH₂CH₂), 2.92-2.79 (1H, m, NCHHCH₂CH₂), 2.29-1.82 (7H, m, NCH₂CH₂CH₂ and CH₂CHCH₂Si), 1.59 (1H, s, NH), 0.88 (1H, dd, J 16 and 5 Hz, CHHSi), 0.70 (1H, dd, J 16 and 5 Hz, CHHSi) and 0.06 (9H, s, Me₃Si).

¹³C NMR (100 MHz, CDCl₃, picrate salt) δ 162.35, 141.71, 128.00, 126.54, 75.48, 55.65, 55.40, 41.85, 34.11, 29.26, 24.71, 19.83 and -1.06.

HRMS (EI) (Found: M⁺, 197.1600. C₁₁H₂₃NSi requires M, 197.1601).

m/z 197 (9.2%, M⁺), 126 (49, C₈H₁₆N), 83 (100, C₅H₉N).

J-5323-8

Pyrrolizidine (\pm)-**8d** (quench with PhCHO, 41%)

Two diastereomers (1:1).

M.p. 140-143 °C of picrate salt.

*R*_F [CH₂Cl₂-MeOH (9:1)] 0.55.IR (CDCl₃, picrate salt) 2965 (C-H), 1565 cm⁻¹ (NO₂).

¹H NMR (400 MHz, CDCl₃, picrate salt) δ 8.84 (2H, s, C₆H₂ of picrate), 7.39-7.26 (5H, m, Ph), 4.79-4.71 (1H, m, CHOH), 4.18-4.08 (0.5H, m, NCHCHCH₂CO), 4.08-4.00 (0.5H, m, NCHCHCH₂CO), 4.00-3.89 (1H, m, NCHHCH₂CHCH₂CO), 3.74-3.57 (1H, m, NCHHCH₂CHCH₂CO), 3.13-3.00 (1H, m, NCHHCH₂CH₂), 2.83-2.79 (1H, m, NCHHCH₂CH₂), 2.34-1.87 (10H, m, NCH₂CH₂CH₂, CH₂CHCH₂CO, NH, CHHCHOH), 1.89 (0.5H, ddd, *J* 15, 9 and 3 Hz, CHHCO) and 1.23 (0.5H, ddd, *J* 18, 12 and 6 Hz, CHHCO).

¹³C NMR (100 MHz, CDCl₃, picrate salt) δ 162.27, 143.96, 143.75, 141.64, 128.82, 128.77, 128.23, 128.07, 128.05, 126.60, 125.59, 125.57, 73.01, 72.81, 72.76, 72.62, 55.39, 55.32, 55.22, 55.15, 42.41, 41.92, 41.38, 41.20, 32.69, 32.14, 30.13, 29.86, 25.00 and 24.82.

HRMS (EI) (Found: *M*⁺, 231.1622. C₁₅H₂₁NO requires *M*, 231.1624).*m/z* 231 (84%, M⁺), 214 (100, M-OH), 124 (94, C₈H₁₄N).